便携式常温体外肺灌注联合Organ Care System在扩大标准供体肺移植中的应用(EXPAND)
EXPAND单臂关键性试验在美国、德国和比利时8家机构评估便携式常温Organ Care System(OCS)肺灌注通气对扩大标准供体和循环死亡供体肺使用率及移植结局的影响。共灌注评估93对肺,81对符合移植标准,最终79对(87%)被移植;主要复合终点(30天生存且72小时内无PGD3)在43/79(54%)患者中达成,未达到65%预设目标,但30天生存率达99%。
要点
- OCS Lung使87%符合标准的扩大标准供体肺成功用于移植。
- 主要复合终点54%未达65%预设目标,PGD3发生率为44%。
核心结论
- 尽管未达到主要疗效终点,便携式OCS Lung实现了87%的供体肺使用率并取得良好临床结局。
- 许多被其他移植中心拒绝的肺通过该技术成功移植,可能增加全球肺移植数量。
研究设计与样本
- 单臂关键性试验,在美国、德国和比利时8家机构开展。
- 纳入符合至少一项扩大标准(PaO2:FiO2≤300 mm Hg、预期缺血时间>6 h、供体年龄≥55岁或循环死亡供体)的供体肺。
- 受者为成人双肺移植受者,主要分析人群为所有移植受者。
- 主要疗效终点为移植后30天患者生存且72小时内无ISHLT原发性移植物功能障碍3级(PGD3)的复合终点,预设目标值为65%。
主要发现
- 12对肺未满足OCS移植标准,81对适合移植,2对因后勤原因排除,最终79对(87%)符合标准的肺被移植。
- 主要终点在43/79(54%)患者中达成,未达到预设目标。
- 35/79(44%)患者在初始72小时内发生PGD3。
- 78/79(99%)患者移植后30天生存。
临床怎么用
- 对于扩大标准供体肺,可考虑使用便携式常温OCS Lung进行灌注、通气和功能评估以增加可用供肺。
- 需注意主要复合终点未达预设目标,PGD3发生率较高,应个体化评估受益与风险。
局限性
- 单臂设计,未设对照,无法与冷缺血保存直接比较。
- 这些肺若采用冰藏保存能否获得相似结局尚不清楚,需未来研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Donor lung use for transplantation is the lowest among solid organ tranplants because of several complex and multifactorial reasons; one area that could have a substantial role is the limited capabilities of cold ischaemic storage. The aim of the EXPAND trial was to evaluate the efficacy of normothermic portable Organ Care System (OCS) Lung perfusion and ventilation on donor lung use from extended-criteria donors and donors after circulatory death, which are rarely used. METHODS: In this single-arm, pivotal trial done in eight institutions across the USA, Germany, and Belgium, lungs from extended-criteria donors were included if fulfilling one or more of the following criteria: a ratio of partial pressure of arterial oxygen (PaO2) to fractional concentration of oxygen inspired air (FiO2) in the donor lung of 300 mm Hg or less; expected ischaemic time longer than 6 h; donor age 55 years or older; or lungs from donors after circulatory death that were recruited and assessed using OCS Lung. Lungs were transplanted if they showed stability of OCS Lung variables, PaO2:FiO2 was more than 300 mm Hg, and they were accepted by the transplanting surgeon. Patients were adult bilateral lung transplant recipients. The primary efficacy endpoint was a composite of patient survival at day 30 post-transplant and absence of The International Society for Heart & Lung Tranplantation primary-graft dysfunction grade 3 (PGD3) within 72 h post-transplantation, with a prespecified objective performance goal of 65%. The primary analysis population was all transplanted recipients. This trial is registered with ClinicalTrials.gov, number NCT01963780, and is now complete. FINDINGS: Between Jan 23, 2014, and Oct 23, 2016, 93 lung pairs were perfused, ventilated, and assessed on the OCS Lung. 12 lungs did not meet OCS transplantation criteria so 81 lungs were suitable for transplantation. Two lungs were excluded for logistical reasons, hence 79 (87%) of eligible lungs were transplanted. The primary endpoint was achieved in 43 (54%) of 79 patients and did not meet the objective performance goal. 35 (44%) of 79 patients had PGD3 within the initial 72 h. 78 (99%) of 79 patients had survived at 30 days post-transplant. The mean number of lung graft-related serious adverse events (respiratory failure and major pulmonary-related infection) was 0·3 events per patient (SD 0·5). INTERPRETATION: Despite missing the objective primary endpoint, the portable OCS Lung resulted in 87% donor lung use for transplantation with excellent clinical outcomes. Many lungs declined by other transplant centres were successfully transplanted using this new technology, which implies its use has the potential to increase the number of lung transplants performed worldwide. Whether similar outcomes could be obtained if these lungs were preserved on ice is unknown and remains an area for future research. FUNDING: TransMedics Inc.
引用
- Loor G, Warnecke G, Villavicencio MA, et al. Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial. Lancet Respir Med. 2019. PMID: 31378427. doi:10.1016/S2213-2600(19)30200-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。